Sorafenib

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Sorafenib

Examples of brand names: Nexavar [EU/DE]

ATC code: L01EX02

Main use (for orientation): Selected cancers

Documented research summary

Cannabis/sorafenib cell synergy recorded; the cannabis preparation is insufficiently characterised in the abstract and is not treated as evidence for isolated CBD/THC.

Uncertainties and limitations

Human oral single-ingredient product; the authorisation/product information read is a US SPL, not evidence of a German brand.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

Cannabis preparation (not isolated) – laboratory and animal studies

Finding ID: B0182

Type of result: Preclinical evidence

Observation: Concentration-dependent cell synergy at intermediate doses, more ROS/apoptosis in the combination arm.

Mechanism: Transcriptome/stress response

Study type: Cell experiment

Context studied: HepG2 in vitro; cannabis composition not established from the abstract.

Clinical interpretation: Not a clinical treatment recommendation

Limitations and uncertainties: Abstract reviewed; do not transfer in vitro concentrations and effects to medicine use in humans.

Original sources for this finding: Identification of Changes in the Transcriptome Profile of Human Hepatoma HepG2 Cells Exposed to Combined Sorafenib and Cannabis Treatment. [BMED42196320]

References and access status

[V2_LABEL_D0379] SORAFENIB TOSYLATE (SORAFENIB) TABLET, FILM COATED [MYLAN PHARMACEUTICALS INC.]

Original source / bibliographic reference

Authors: Mylan Pharmaceuticals Inc.

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED42196320] Identification of Changes in the Transcriptome Profile of Human Hepatoma HepG2 Cells Exposed to Combined Sorafenib and Cannabis Treatment.

Original source / bibliographic reference

Authors: Udomkritayachai K, Thiamsuk T, Jarujamrat T, Kudikhong P, Raksakhom S, Suphattana P, Khankham N, Thanawong P, Khacha-Ananda S.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.3390/ijms27104342

PMID: 42196320

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility